Daewoong pharmaceutical Co.,Ltd

KSE 069620.KS

Daewoong pharmaceutical Co.,Ltd Free Cash Flow for the year ending December 31, 2023: USD 10.67 M

Daewoong pharmaceutical Co.,Ltd Free Cash Flow is USD 10.67 M for the year ending December 31, 2023, a 175.32% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Daewoong pharmaceutical Co.,Ltd Free Cash Flow for the year ending December 31, 2022 was USD 3.88 M, a 113.31% change year over year.
Daewoong pharmaceutical Co.,Ltd Free Cash Flow for the year ending December 31, 2021 was USD -29.13 M, a -176.85% change year over year.
Daewoong pharmaceutical Co.,Ltd Free Cash Flow for the year ending December 31, 2020 was USD 37.90 M, a 486.73% change year over year.
Daewoong pharmaceutical Co.,Ltd Free Cash Flow for the year ending December 31, 2019 was USD 6.46 M, a 175.56% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

KSE: 069620.KS

Daewoong pharmaceutical Co.,Ltd

CEO	Mr. Chang-Jae Lee
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	12, Bongeunsa-ro 114-gil
Employees	1,710
Sector	Health Care
Industries Pharmaceuticals

Description

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years